Identity
Ecnoglutide is a cAMP-biased GLP-1 receptor agonist studied for weight management.
Selected study only; not a complete clinical review.
Peptide library
Ecnoglutide
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The positive phase III trial concerns Chinese adults without diabetes over a defined period. Population, estimand and formulation must remain attached to the result; indirect percentages do not establish superiority to other drugs.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
664 Chinese adults without diabetes; randomized phase 3 trial.
What the sources found
The highest-dose group had −13.2% mean weight change versus +0.1% with placebo at 40 weeks.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
Ecnoglutide is a cAMP-biased GLP-1 receptor agonist studied for weight management.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Gastrointestinal events were common; ten treated participants discontinued because of adverse events.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The highest-dose group had −13.2% mean weight change versus +0.1% with placebo at 40 weeks.
Selected study only; not a complete clinical review.
Adverseeffects
Gastrointestinal events were common; ten treated participants discontinued because of adverse events.
Selected study only; not a complete clinical review.
References
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2025.
PMID: 40555243
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.